Swedish cancer diagnostic company Elypta’s urine test has been able to accurately identify 90% of patients with recurrent kidney cancer.
The business announced the intermediary results from its prospective multi-centre trial designed to determine if urine-collected glycosaminoglycans (GAGomes) can be used for the early detection of cancer recurrence. Specifically, following curative surgery in patients with high or intermediate risk of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer.
Go deeper with GlobalData
Elypta announced the early results as part of the 2025 European Association of Urology Congress, taking place in Madrid, Spain. The trial was co-funded by the European Union’s Horizon 2020 research and innovation programme and took place at 29 international locations. The trial featured an adaptive design with primary endpoint analysis carried out after 30 events or recurrences had been reached.
The company says the results underline the ability of clinicians to pivot away from the use of radiological examination for post-treatment patients, instead pushing for the use of patients’ submitted urine samples as routine observation.
Now, Elypta claims that the study’s second patient cohort is nearing final recruitment, with validation results expected later this year.
Elypta chief medical officer Volker Liebenberg said: “A urine test can offer a less invasive and more comfortable alternative for post-operative monitoring, potentially transforming kidney cancer follow-up care.”
Commenting on results from the AUR87A trial, Elypta CEO Karl Bergman said: “These findings show the potentially transformative impact a urine-based test may have in the surveillance of recurrent disease for kidney cancer patients.”
Elsewhere in the field of cancer diagnostics, Proscia has secured $50m to advance its AI-driven digital pathology platform designed to allow clinicians to interpret whole slide images.
